23 October 2020
The Vector State Research Center of Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing has detected over 80 mutations of the coronavirus yet they do not affect the effectiveness of the developed vaccine, the center’s General Director Rinat Maksyutov reported on Wednesday (October 21).
“The Vector Center is additionally conducting extensive studies of the genetic variability of the novel coronavirus in all Russian regions. <…> We constantly perform whole-genome sequencing and detect possible mutant variants. To date, we have detected over 80 nucleotide substitutions which are not included in international databases. But these changes are not critical and do not influence the effectiveness of the peptide vaccine developed,” he said at the 17th annual meeting of the Valdai International Discussion Club.
The coronavirus vaccine developed by Siberia’s Vector Center is safe for people with allergies or chronic conditions and seniors, the general director of the center said Wednesday. “The vaccine is fully safe both for healthy volunteers, people with chronic conditions or allergies and seniors.”
The trials showed that the vaccine has high immunogenicity properties. “We confirmed that the peptide vaccine showed both the high safety profile and high immunogenicity in the conducted clinical trials involving 100 volunteers as all volunteers who received the shot had an immune response. This sampling gives us proof of the protective effectiveness in the framework of the conducted epidemiological research,” Maksyutov pointed out.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024